TY - JOUR T1 - Characterization of CCX140-B, an orally bioavailable antagonist of the CCR2 chemokine receptor, for the treatment of type 2 diabetes and associated complications JF - Journal of Pharmacology and Experimental Therapeutics JO - J Pharmacol Exp Ther DO - 10.1124/jpet.111.190918 SP - jpet.111.190918 AU - Timothy J Sullivan AU - Daniel J Dairaghi AU - Antoni Krasinski AU - Zhenhua Miao AU - Yu Wang AU - Bin N Zhao AU - Trageen Baumgart AU - Rob Berahovich AU - Linda S Ertl AU - Andrew Pennell AU - Lisa Seitz AU - Shichang Miao AU - Solomon Ungashe AU - Zheng Wei AU - Dan Johnson AU - Landin Boring AU - Chia-Lin Tsou AU - Israel F Charo AU - Pirow Bekker AU - Thomas J Schall AU - Juan C Jaen Y1 - 2012/01/01 UR - http://jpet.aspetjournals.org/content/early/2012/06/04/jpet.111.190918.abstract N2 - The following manuscript was published as a Fast Forward article on February 29, 2012: Sullivan TJ, Dairaghi DJ, Krasinski A, Miao Z, Wang Y, Zhao BN, Baumgart T, Berahovich R, Ertl LS, Pennell A, Seitz L, Miao S, Ungashe S, Wei Z, Johnson D, Boring L, Tsou C-L, Charo IF, Bekker P, Schall TJ, and Jaen JC, Characterization of CCX140-B, an orally bioavailable antagonist of the CCR2 chemokine receptor, for the treatment of type 2 diabetes and associated complications. J Pharmacol Exp Ther jpet.111.190918; doi:10.1124/jpet.111.190918 It was later found that the chemical identity of a compound cited in the article, CCX140-B, was not sufficiently disclosed. The authors are unable, at this time, to provide the chemical identity of CCX140-B in accordance with the editorial policies of The Journal of Pharmacology and Experimental Therapeutics. As a result, the authors have voluntarily withdrawn this manuscript from publication. We apologize for any inconvenience this may cause JPET's readers. ER -